Bli medlem
Bli medlem

Du är här


Panion: Panion acquires access to dog study

Panion has made an agreement with Copenhagen University about transfer
and use of technical data from a study in dogs.

The study is conducted by well-reputed researchers and is very
relevant for Panion's development of our gene therapy product for
dogs with epilepsy. The study is not yet published by the
researchers, but Panion may use the data in the contact with FDA and
other authorities to speed up the development process from the day
the agreement is signed.

"We are very pleased with the agreement, and we expect that this will
ease our way to the next trial for our innovative product and to the
market" says Anja Holm,

CEO of Panion Animal Health.
Anja E. H. Holm, SEO
+ 45-22 94 66 00

This press release contains information which Panion Animal Health AB
is obliged to publish according to the EU market abuse regulation
(MAR). This information was submitted by Panion's CEO, Anja E. H.
Holm, for publication on August 14 2017.

Bolaget ska utveckla och kommersialisera genterapi för behandling av
epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla
och kommersialisera andra veterinärmedicinska produkter och nya
behandlingsformer som kan ge sjuka djur bättre livskvalitet.

Panion will develop and commercialize a gene therapy treatment for
dogs with drug refractory epilepsy, and other new animal health
products and treatments that improve the quality of life for animals
suffering from chronic diseases.


Författare Aktietorget

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.